Circulating immune checkpoints predict heart failure outcomes

Circulating immune checkpoints predict heart failure outcomes

Abstract Aims There are limited data examining the role of immune checkpoint (IC) ligands in the pathophysiology of heart failure (HF). Therefore, we explore this in three HF animal models and in three different human cohorts (healthy, stable, and worsening HF). Methods and results Transcriptomic an...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron:	Elles M. Screever, Laura I.E. Yousif, Javid J. Moslehi, Joe‐Elie Salem, Adriaan A. Voors, Herman H.W. Silljé, Rudolf A. deBoer, Wouter C. Meijers
Fformat:	Erthygl
Iaith:	English
Cyhoeddwyd:	Wiley 2023-08-01
Cyfres:	ESC Heart Failure
Pynciau:	Immune checkpoints PD‐L1 PD‐L2 Galectin‐9 Heart failure
Mynediad Ar-lein:	https://doi.org/10.1002/ehf2.14304

Eitemau Tebyg

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
gan: Douglas B. Johnson, et al.
Cyhoeddwyd: (2019-05-01)

Checkpoint Inhibition in Myeloma: Opportunities and Challenges
gan: Federica Costa, et al.
Cyhoeddwyd: (2018-09-01)

The role of immune checkpoints in cardiovascular disease
gan: Laura I. Yousif, et al.
Cyhoeddwyd: (2022-10-01)

Enhancing cancer care with improved checkpoint inhibitors
gan: Vickram A S, et al.
Cyhoeddwyd: (2024-10-01)

Checkmate with checkpoint inhibitors: New paradigm in immunotherapy
gan: Ruby Dhar, et al.
Cyhoeddwyd: (2023-04-01)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
gan: Kazuhiko Hashimoto, et al.
Cyhoeddwyd: (2020-07-01)

Immune Checkpoint in Glioblastoma: Promising and Challenging
gan: Jing Huang, et al.
Cyhoeddwyd: (2017-05-01)

Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy
gan: Juwon Lee, et al.
Cyhoeddwyd: (2021-07-01)

Overview of the Cardiotoxicity Induced by PD-1/PD-L1 Immune Checkpoint Inhibitor in Critical Care
gan: Ruiting Li, et al.
Cyhoeddwyd: (2021-06-01)

On Demand Biosensors for Early Diagnosis of Cancer and Immune Checkpoints Blockade Therapy Monitoring from Liquid Biopsy
gan: Sai Mummareddy, et al.
Cyhoeddwyd: (2021-12-01)

PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
gan: Tianrui Yang, et al.
Cyhoeddwyd: (2021-02-01)

PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy
gan: Jan Willem Kleinovink, et al.
Cyhoeddwyd: (2017-04-01)

Epigenetic modifications of the immune-checkpoint genes CTLA4 and PDCD1 in non-small cell lung cancer results in increased expression
gan: Sebastian Marwitz, et al.
Cyhoeddwyd: (2017-05-01)

Immune Checkpoint Inhibitors in Cancer Therapy
gan: Yavar Shiravand, et al.
Cyhoeddwyd: (2022-04-01)

Research Progress on Cardiotoxicity of PD-1/PD-L1 Immune Checkpoint Inhibitors
gan: YU Lin, et al.
Cyhoeddwyd: (2021-08-01)

The Role of Immune Checkpoint Inhibitors in Cancer Therapy
gan: Ahmed M. Basudan
Cyhoeddwyd: (2022-12-01)

The role of immune checkpoint inhibitors in prostate cancer
gan: Gabriel Surdacki, et al.
Cyhoeddwyd: (2019-03-01)

Editorial: The Roles of Checkpoint Inhibitors in Inflammatory Diseases
gan: Andreas von Knethen, et al.
Cyhoeddwyd: (2021-10-01)

Activity and Safety of Immune Checkpoint Inhibitors in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis
gan: Alberto Bongiovanni, et al.
Cyhoeddwyd: (2021-05-01)

Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
gan: Ya Xu, et al.
Cyhoeddwyd: (2020-10-01)

Structural Characterization of a Macrocyclic Peptide Modulator of the PD-1/PD-L1 Immune Checkpoint Axis
gan: Edyta Zyla, et al.
Cyhoeddwyd: (2021-08-01)

The Neonatal Innate Immune Response to Sepsis: Checkpoint Proteins as Novel Mediators of This Response and as Possible Therapeutic/Diagnostic Levers
gan: Emily Hensler, et al.
Cyhoeddwyd: (2022-07-01)

Key questions about the checkpoint blockade-are microRNAs an answer?
gan: Mihnea Dragomir, et al.
Cyhoeddwyd: (2018-06-01)

Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer
gan: Maria Georganaki, et al.
Cyhoeddwyd: (2018-12-01)

Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEA
gan: William L. Redmond, et al.
Cyhoeddwyd: (2023-02-01)

The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors
gan: Reid P. Bissonnette, et al.
Cyhoeddwyd: (2021-08-01)

Advances in immune checkpoint inhibitors for hepatocellular carcinoma
gan: Ji Won Han, et al.
Cyhoeddwyd: (2021-09-01)

Immune Checkpoint Inhibitors: Ctla-4 and Pd-1/Pd-l1 in Immunotherapy
gan: Kübra KAHVECİ, et al.
Cyhoeddwyd: (2019-12-01)

Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation
gan: Zachary S. Buchwald, et al.
Cyhoeddwyd: (2018-12-01)

Safety and efficacy of PD-1/PD-L1 immune checkpoint inhibitors in patients with pre-treated advanced stage malignant mesothelioma: a systematic review and meta-analysis
gan: Amjad Zafar, et al.
Cyhoeddwyd: (2024-11-01)

The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors
gan: Jiaxin Zhou, et al.
Cyhoeddwyd: (2022-07-01)

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
gan: Adel Naimi, et al.
Cyhoeddwyd: (2022-04-01)

Editorial: Biomarkers of Immune-Checkpoint-Inhibitor Immunotherapies in Hepatocellular Carcinomas
gan: Zhanjun Guo, et al.
Cyhoeddwyd: (2022-03-01)

Profiling targetable immune checkpoints in osteosarcoma
gan: Troy A McEachron, et al.
Cyhoeddwyd: (2018-12-01)

The Use of Phytochemicals to Improve the Efficacy of Immune Checkpoint Inhibitors: Opportunities and Challenges
gan: Deniz Can Guven, et al.
Cyhoeddwyd: (2022-10-01)

Commentary: Chronic PD-1 Checkpoint Blockade Does Not Affect Cognition or Promote Tau Clearance in a Tauopathy Mouse Model
gan: Kuti Baruch, et al.
Cyhoeddwyd: (2020-05-01)

NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapy
gan: Leona Raskova Kafkova, et al.
Cyhoeddwyd: (2024-02-01)

Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer
gan: Shuai Wang, et al.
Cyhoeddwyd: (2018-08-01)

PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells
gan: Silvia Pesce, et al.
Cyhoeddwyd: (2019-06-01)

In Search of Better Peptide-(Derived from PD-L2)-Based Immune Checkpoint Inhibitors
gan: Boris Klebansky, et al.
Cyhoeddwyd: (2024-05-01)